Finally, phase 2 data! Inside BiomX's successful phage therapy trial with CEO Jonathan Solomon
The conversation
Episode notes
BiomX CEO Jonathan Solomon joins Jessica Sacher and Joe Campbell to explain the choices behind the company’s reported phase 2 results in diabetic foot osteomyelitis. Listeners learn how matching phages to infections, choosing delivery methods and consulting clinicians shaped the studies, alongside the limits of the evidence and questions left unresolved.
Solomon reports tissue buildup over exposed bone in twelve of 13 phage recipients versus five of nine placebo recipients after twelve weeks, with both groups also receiving antibiotics.
For the planned larger cystic fibrosis study, Solomon describes extending treatment to two months and adding an antibiotic run-in period to reduce interference from bacterial fluctuations after antibiotic changes.
The diabetic foot study used one selected phage per patient, and Solomon reports no observed resistance while cautioning that follow-up ulcer swabs provided messier measurements than screening bone biopsies.
Episode timeline
- 0:00 Introduction to Jonathan Solomon and the diabetic foot results
- 5:16 What the cystic fibrosis studies could establish
- 16:00 Diabetic foot treatment delivery and personalized phage selection
- 30:53 Using clinician input to define meaningful improvement
- 39:23 Funding uncertainty and the commercial case for phages
- 50:08 Regulatory discussions, biofilm research and future goals
Transcript
AI-transcribed and edited for readability. May contain errors or omissions; check the recording for exact wording.
Select a word or timestamp to listen. Use arrow keys to move between words.
- Jessica Sacher
Hello, welcome to Podovirus Podcast. We are back. Joe and I are here. And today we have Jonathan Solomon, who is the CEO of BiomX. So we are thrilled to talk to him because they listened to my wish I put out in the universe. And I said, we need a positive phase two clinical trial for phages. Why hasn't anyone done that in decades? Actually, well, more than a decade?
Jonathan said, Okay, I'll do that for you, and then he agreed to come tell us about it. Because BiomX just finished a phase two clinical trial of diabetic foot ulcer. So this is also a clinical indication that I feel like the phage field has been always kind of seeing as like, why don't we just address that? Maybe that's the low hanging fruit, or maybe it's really hard because it still hasn't happened. Even though so many people agree that it would be an obvious indication, cause you can get the phages to the site and you know, they should work, and that's a very debilitating problem.
So Jonathan's gonna tell us how they did this, and yeah, what that means. And we have a bunch of our usual questions for him that we've been asking in our phage therapy series about, kind of what the hurdles are for him these days pushing forward a company in the phage therapy space, and what he sees for the future. So welcome, Jonathan, and maybe you can give us a little intro of how you came into phage. You had a life before phage.
We can hear whatever you'd like to tell us.
- Jonathan Solomon
Sure, so Jessica, Joe, thank you for having me. Quite excited. I've listened to your podcast and enjoyed it. And we know it's a small community, right? And it's great to kinda have this. And the more we talk to each other, the more we learn from each other, the better, and we're quite excited. I think this is quite an inflection point and hopefully, there'll be many more.
So my background is a little bit unusual. I am Israeli; you can see from the hairstyle. I actually served 10 years in a classified unit, which I cannot talk about. Then I came to Boston, got my MBA, launched my first company, which was related to phage, but not directly phage that kill bacteria. And after ten years in the States, when our second son was born, my wife notified me that we are moving back to Israel, and she's also in a classified unit.
So you definitely don't wanna mess with her. And then, I was kind of like, taking it easy, thinking what to do. Actually kind of fantasized about a PhD in phage and got to do some work at the lab of Weizmann Institute researcher Rotem Sorek. And they were in the process of launching a small phage company together with Eran Elinav, two of the big names of the Weizmann Institute, as well as funding from OrbiMed, which is a founding investor together with Takeda and J&J.
And I kind of started for a bit and said, Hey, I really want to get my PhD. Maybe I'll be on the board. But, you know, I kind of found myself a few months after that leading the company. So that's kind of how things started. We've evolved through the years, you know, we kind of rode the wave of like excitement around microbiome and looked into IBD as well as acne.
And then even went public, which was fun for a while, less fun afterwards.
And we're fortunate to kind of build together a team that said, Look, it's going to be really tough. Phage is a really tough modality. Let's kind of focus on an indication that at least we know there's no risk on the target, meaning that the target is validated. We know that there are challenges with the modality, right? The phage, and let's focus on cystic fibrosis. We focused everything on cystic fibrosis.
Fortunate to have two clinical studies, the readout in February 2023 and then in November 2023, which actually showed really interesting activity. I think the most dramatic thing that we saw there was that three out of 21 patients on the phage arm actually got rid of their infection altogether. So that's what's called bacterial conversion, that's dramatic. That does not happen spontaneously in, you know, in chronic CF infections that are there for like 18 years.
One of the patients was infected for 35 years and after a few days of phage treatment got rid of it, right? So that was exciting. Again, it's not the clinical data that we've now seen in the diabetic foot study, but in terms of microbiology, we saw a really interesting signal. That got, Deerfield excited, together with the CFF Foundation. They actually kind of went together and put together a large financing.
And as part of that round, we basically merged with Adaptive phage, right? And that brought the DFO program. So much, much of the credit in the diabetic foot osteomyelitis program goes to the folks at Adaptive Phage and their thinking, right? The study was already like a year into enrollment, even more, and basically we took it, we took it, you know, worked on it, kind of streamlined.
There's a lot of work on, you know, managing CROs, et cetera. But that's kind of the background, I think, to where we are today. Again, very excited with the diabetic foot program, CF study, and we're about to launch the phase two B, so hopefully kind of two shots on goal. That'll be interesting, but definitely the diabetic foot study is where we're seeing not only the microbiology effect that we've seen in the CF study, but actual clinical effect with statistical significance.
- Jessica Sacher
Amazing, thank you. Before we dive into the diabetic foot trial, I feel like a lot of people have questions about the CF trial too. And so why do you think that there wasn't a clinical effect that you wanted to see with that one?
- Jonathan Solomon
So here, I think the answer is pretty straightforward. It's too short, right? And too few patients, right? So this is only ten patients that we've dosed, you know, twice a day. Interestingly, we had an earlier small, like a nine patient study beforehand, which is a pilot study. Again, everything is done hand in hand with the CF Foundation. They've been kind of the guiding light in how to go about it, interestingly, and I think we should talk about also the diabetic foot study.
A lot of the thinking was guided by compassionate use cases, right? So there is a lot of data out there, right? We could be skeptical about the data, but it still serves as a guideline. And both the CF study as well as the DFO study kind of followed the paradigm that was set in the compassionate use cases, right? So in the CF study, we did a small study. That was nine patients that we started with.
Like one day placebo, second day low dose, third day a high dose, and then four consecutive days of a high dose twice a day, right? And we knew from the compassionate use cases, you need ten days to really see a microbiology effect. So here we did see some reduction over, like a log reduction between treatment and placebo. Interestingly, one of the patients that had a three log reduction, right?
So 99.9 percent reduction of bacterial load. The physician called us a few months later and said, Hey, this patient doesn't have the infection anymore. So this is like a patient I've been treating for many years and boom, the bacteria's gone, right? So that was encouraging. We launched a part two. Again, it was 34 patients dosed for ten days, right? So it's not enough to see kind of the clinical effect that you want to see, meaning improvement in lung capacity or patient reported outcome.
Not in terms of duration, not in terms of, like, the power of the study, right? So I think we weren't expecting. We did see some signals, I would say in FEV1 and in patient reported outcome. But again, I think it's such a small number that we shouldn't be hanging our hat on it. Some interesting signal, you know, until we do a larger study, and that's a phase two B with 60 patients for two months.
We can't say anything, but the microbiology, we did see this effect. I will say, by the way, another key important takeaway is that the background antibiotics were having a lot of effect, right? So in both our studies, DFO and CF, right? Placebo is getting antibiotics and treatment is getting antibiotics plus phage. So you can see in CF, some of the patients have this.
Like they do one month on, one month off, or one month one type of antibiotic and one month another type of antibiotic, right? You would imagine that after like ten years of this regimen, these fluctuations around the, you know, changing antibiotics would kind of stop. They don't, right? So I think that kind of created a lot of fluctuation that we saw. But again, we did see this kind of hard endpoint of like bacterial conversion, which is convincing. Again, trends in clinical endpoints.
But, you know, I don't think it's sufficient to really say, hey, we're seeing something dramatic here
- Joe Campbell
For details, can you talk about what the primary endpoints were and how you decided on them?
- Jonathan Solomon
In the CF study or the DFO study?
- Joe Campbell
Yeah, and well, I'll start with the CF study.
- Jonathan Solomon
CF study was pretty straightforward, you know? Again, it's only a phase 2a, so the primary was safety and tolerability. We all know phage are safe, right? So that's a low hanging fruit. But that was good to see. And then, all the exploratory were microbiology, right? Whether we can reduce bacteria or see bacterial conversion. FEV1, which is basically the volume that the patient can kind of breathe, as well as what's called CFQR, which is a patient reported outcome.
And we did see trends, we did see trends in FEV1 and CFQR, which was great to see. I mean, you know, in the 90s, when there wasn't a lot of antibiotic resistance, when you treated patients with antibiotics, you did see an effect within a couple weeks, right? So it was encouraging. And again, I think the dramatic result that we saw in the bacterial conversion, which is what we got excited about.
- Joe Campbell
Yeah, just if I could ask another follow-up In terms of exclusion inclusion criteria, were you selecting? The patients were included based on them having an infection of what bug? And did you screen to make sure that the patients were sensitive to the phages you were using? The sort of the nuts and bolts of
- Jonathan Solomon
So yes, yes to both, yeah, yes to both. And I think that's crucial. And we'll probably talk more about it, both on the DFO and CF, right? So we made sure that the patients in the CF study had Pseudomonas aeruginosa. We took, you know, sputum samples, we cultured them. We then made sure that they're sensitive to our phage, and those were the only patients that were enrolled on the study, right?
Same in DFO, which made it even more challenging, right? We literally took bone biopsy and cultured the bacteria, and there was a major dropout. Because not all the centers know how to do a bone culture or a bone biopsy and grow bacteria out of it, right, successfully. So, you know, as I think we think about the takeaways, we're very, very conservative in making sure that the patients had the bacteria and that the bacteria were sensitive to our phage.
And I suspect that that's one of the key, you know, reasons for success. I will also say one needs to be careful, even more so in the CF study, that there are high levels of bacteria, right? Because if you wanna see a drop in the levels of bacteria, and we know that, you know, CFU measurements are noisy, you wanna make sure you have a high level of bacteria so you can see the drop, right?
So that's also crucial. I suspect some of the studies that had low levels of bacteria, right? If they don't have the dynamic range, they just won't see the effect. Either way.
- Jessica Sacher
Yeah, oh, there's so many questions, I guess. First, just to finish up on the CF trial. Yeah, like, will you design? So the results that you got were positive enough that led you guys to decide to design a larger study. And do you change anything about the design in the larger study based on what you learned from that one?
- Jonathan Solomon
So I think the most important thing is the duration, right? So I think what we saw in the phase two, what we did is we tried to synchronize the phage treatment together with when they started a new antibiotic, right? It was only ten days. So what we saw is that when you change an antibiotic, or, you know, the patient kind of did not take an antibiotic for a month and then start taking an antibiotic for a month, right?
There'd be like a few days that the bacterial levels are kind of fluctuating, and then after a while it stabilizes, and I think that's something that if you dose long enough, right? You're not going to see that because you don't care, because it all averages out. And to be even extra cautious, we kind of made sure there's a run-in period. So the patients will start the antibiotics, you know, first. A few days later, they will start the phage treatment.
Interestingly, to that point, the patients, and this was pre-specified, the patients who were taking antibiotics, the same antibiotics all the time. We saw a three log reduction in the bacterial count, right? It's a very clean signal. So I think in those patients that are alternating or cycling, that's kind of the terminology, right? Whether they're taking, you know, TOBI and aztreonam, one month, one month, or they're taking TOBI for one month.
And then, you know, antibiotic holiday for one month. Those are the patients that got to be careful. And I think that's where you might ensure you dose long enough and there's a run-in period. So I think that's a key takeaway. Except for that, we want to make sure again we have those patients that are on continuous antibiotics and we make sure that there's high level of bacteria to begin with.
I think that's key. Two key takeaways are as we're trying to differentiate, right? Instead of asking, why did we see activity here and others have not? And again, compassionate use cases where the bacterial levels tend to be higher, they did see an effect, right? So it kind of holds together nicely.
- Joe Campbell
So, if I could ask another question, can you tell me what the route of administration was and how you decided upon that route for the CF study?
- Jonathan Solomon
So it was nebulized, yeah, it was nebulized based on compassionate use cases. And I think Jessica kind of mentioned earlier, route of delivery for phage is crucial, right? Because what we've learned, by the way, the hard way. In our early days, we had an acne study and we thought, Hey, this is like a super low hanging fruit, just test it. We literally undertook an initial clinical study where we saw, sort of, that the phage can actually reduce bacterial levels on the skin, right, with a skin swab.
But the bacteria are actually inside the sebaceous gland. You got to penetrate really deep and we had no ways of modeling it. There were no compassionate use cases, kind of build that case, and it just didn't work, right? So I think that was our takeaway, which is like, you know, phage is a very large molecule. Delivery is not trivial. And you know, if it dries on your skin, it probably doesn't sort of propagate, so you got to be very cautious.
So I think our thinking is always like, better to be in a sort of liquid environment. B, better to base it on compassionate use cases, right? When there's some evidence that stuff works, right? IV, there's a lot of compassionate use cases that work. Topical in a wound is what we had in DFO; and nebulized, quite a lot of cases show that it worked pretty well.
- Joe Campbell
How much did you experiment with different nebulizers? That's, I guess, what I'm getting at.
- Jonathan Solomon
Quite a lot, quite a lot, quite a lot. We built a whole setup in our labs and, you know, worked with nebulizers and drop size and everything. And again, fortunately, there's good models for that. But we did all the work to make sure that the phage are intact and that the droplets are a size that penetrate deep into the lung structures. So we try to maximize what we can to kind of reduce the risk as we enter the clinical study,
- Joe Campbell
That's, yeah, it seems like those are some of the important things.
Out of curiosity, when you're picking nebulizers, is there any aspect of, I mean, how far down the road are you thinking? Are you thinking if this is the way we have to nebulize it, that it might be easier or harder for people to self-administer once the product hopefully is approved and in the market, is that something that you're already thinking about?
- Jonathan Solomon
It is, because I think there's a precedent, right? These guys, these patients are taking TOBI nebulized, right? So there's a mindset they already know they wanna do it, not too long, right? There's a bunch of products on the market, so at least there are benchmarks. And you're trying to optimize, of course, commercial availability, you know, patient access, patient ease, how easy it is to work with a company that produces the nebulizers, right, and the performance of the nebulizer.
So, you know, it's a big matrix of parameters.
- Jessica Sacher
While we're on this subject of delivery, I think this is a really good segue to the diabetic foot trial. Because I noticed you used IV in the first dose and then the subsequent doses were not IV, but only topical, right? How did you get at that setup?
- Jonathan Solomon
so again, I think this is all credit to the folks at Adaptive phage. And I think the rationale was to follow compassionate use cases, right? Adaptive was involved in some of the compassionate use cases, providing phage to that. And there's quite a few publications. And I think the rationale was a bit like oncology, right? Like a single dose for like debulking whatever bacteria is sort of available from the IV route, and then topicals to trying to break down biofilm.
And that would take a longer time to have the effect. So that's the rationale. I will say, you know, interestingly, when you look at the literature, right? Osteomyelitis kind of sticks out as one of these indications that there's more data in compassionate use cases than others, right? And you sort of say, Hm, why is that, right? Like, I think we all know, right, those compassionate uses are successful, less successful.
And again, the literature search that we've done, and obviously Adaptive has done at the time, osteomyelitis and diabetic foot kind of stick out as one of those indications that there's more efficacy. There's, for example, a paper coming out of Fish of Washington University of 11 out of twelve patients started having like a very positive response in diabetic foot. And I think as we try to think about right, you can say, okay, there's poor blood supply, right?
So antibiotics are not getting to the site of action. So maybe phage, because it amplifies, will have an advantage. B, a lot of antibiotic resistance, right? A lot of MRSA and some of the other nastier bugs. Okay, makes sense, phage will be orthogonal, and three, there's a ton of biofilm, a lot of biofilm load in the indication, right? So again, I think it's these three aspects. Again, we can theorize, right?
It's hard to measure all these things, but I think at least that gives the basis why you're seeing greater efficacy in DFO, already in compassionate use cases. And again, our rationale, the folks at Adaptive, that's why we like them and sort of bonded with them quite quickly, is to say, Okay, there's a lot of data out there, let's try to kind of integrate all the data out there in the literature to improve the chance of success.
Right? We know it's already so tough, right? So let's kind of minimize the risk as much as we can.
- Jessica Sacher
Yeah, and do you also think so? I think, I wanna talk about how you chose which phages. And I noticed, I think on one of your slide shows that you guys have on your website that you are using. It's a personalized approach here, where there's a bank of phage that each patient might get a different set of phages from. Can you talk about that a little bit, and how big is your bank of those phages? Things like that.
- Jonathan Solomon
So APT has a bank of like 200 phage, right? Roughly less than a quarter is phage for Staph aureus. So this is quite a lot. The ideal is to use the platform, the PST platform, to kind of optimize which phage to use. Together with, you know, all the parameters, like what antibiotic the patient is taking, whether there is biofilm. Try to optimize all the parameters and actually give a single phage to that patient, right?
So it's kind of optimize all the parameters,
- Jessica Sacher
Oh, a single phage, interesting.
- Jonathan Solomon
It's a single phage. So it says, okay, use this phage for this patient, right? So that's kind of the way it works. Yeah, trying to optimize, you know, sensitivity, you know, background antibiotics, biofilm and whatever growth curve information we can produce.
- Jessica Sacher
Interesting. So, okay. So they only each get one phage. How many times do you feel like? Or do we probably know? Or if you can say how many times are the patients getting the same phage? Like, did you see certain phages pop up as just like the best choice most of the time?
- Jonathan Solomon
Yeah, I will say, I think we have experience already at BiomX with Staph aureus, right? Like, I think Staph aureus, very much like acne is one of these bacteria that you need fewer phage to kind of get coverage. You do see like these phage that outperform the others, and I think that kind of informs, as we think about the next steps. We have seen some phage, which are again like this, like the C. acnes bacteria, you know, probably like two phage give you like 90 percent coverage of all different strains that we've seen, at least in our labs, versus like some of the others, which are much tougher, like Klebsiella, right?
A lot of diversity, a lot of genomic diversity, meaning that it's much harder to come out with, you know, a single cocktail that has broad host range. So I think it's a trade off, right? I think there are some cases which lend themselves more to this personalized approach, some cases will lend themselves to a cocktail approach.
- Joe Campbell
So with a single phage? And of course, this is obvious, but a lot of people get very worried about resistance. The bacteria evolve resistance to the single phage. And one of the rationales for using a cocktail is that you have a chance that one of the other phages will kill the resistant one. So How concerned are you about resistance when you use a single phage, and what do you do to mitigate those concerns?
- Jonathan Solomon
Great question, right? I think we now have perspective from both aspects, right? So CF study, we have used a cocktail, right? We built a cocktail for Pseudomonas. We treated again. Albeit it was much shorter, it was only ten days, twice a day. We have not seen resistance evolve at all, right? So it's a cocktail on top of antibiotics here. In this study, we have not seen resistance evolve either, right?
Bear in mind, it's also on top of antibiotics. But I think we have to be careful in the way we measured it, just because we're taking a swab from the ulcer, which is not unlike the screening, which is a bone biopsy, which is very clean, right? Toward the end of the study, we took swabs from the ulcer itself, which is a bit of a messier measurement. So we're not seeing resistance emerge, so that's kind of the data. Again, I think resistance on top of antibiotics is less likely, so currently the data we've not seen it again.
I think in the case of Staph aureus, we have the option to move kind of straightforward with a cocktail again. We'll finish analyzing all the information, but based on what we've seen to date, we have not seen resistance emerge. And again, the personalized approach kind of allows you, if you see resistance emerge, you can switch a phage if you want to.
- Joe Campbell
Right? And so if I could just follow up, did you look to see if just in a test tube you see resistance? Because, you know, there's these reports that when bacteria become resistant to phages, sometimes they are no longer as resistant to antibiotics, or they're no longer virulent.
And those are reasons why you might not see it. And so, I guess the simple question is, do you see resistance in the test tube?
- Jonathan Solomon
Of course, if you wait long enough. But in none of the cases was this, you know, resistance kind of developed faster than with the antibiotics that were tested, right? So whatever it is, even a single phage is better than a given antibiotic from at least the data that we have.
- Jessica Sacher
Yeah, so on the zooming out to this trial versus other trials, I feel like, and maybe we can remind the audience, has there ever been a diabetic foot trial with phages that has been, you know, controlled trial and actually gone to completion before this one?
- Jonathan Solomon
Not that we're aware of. I mean, we've seen, I think there were a few small ones from the European companies. But, you know, it was like just a handful of patients that we've seen, and then quite a lot of compassionate use cases, just from what we're aware.
- Jessica Sacher
Do you have a sense of why that is like, why didn't anybody? If this is low hanging fruit, or maybe it's not, but why hasn't anybody tried to do that? Has it just been about raising the funding, getting all the ducks in a row, or any other reasons you can see?
- Jonathan Solomon
I sense, you know, I sense that it just requires a lot of resources. Like, I think this study has been going on for more than two years. As I said, like, because we've insisted on taking bone biopsy and growing bacteria out of it and making sure that the phage are sensitive to those in the bone. Those are very careful screening criteria, with long, you know, sort of long dosing and quite a complicated regimen.
My sense, right? You know, again, I'm sure everyone kinda knows the inside story, right? But you know, I get the sense that a lot of it is just the financial resources you need to put into a study like that. Beyond that, we all know, right, like we all have, like, our, you know, phage lore, right? There's, you know what I call precision medicine, right?
The fact that you, unlike antibiotics, you have to make sure that the patient has the bacteria. We know that, you know, sometimes the bacteria kind of change seasonally in some of the infections, right? So making sure that it's not just a typical infection with a typical bacteria, but you know which bacteria are there. And you've verified that your phage is sensitive to it, right? There's been a lot of issues on manufacturing through the years.
I mean, you know, we've raised north of 200 million, right? There is a lot of knowledge in the company that was learned, some of it the hard way, right? So we all know, right? Like, manufacturing is complicated. And you know, you gotta make sure that the titers are high, you gotta make sure that they stay high, you gotta make sure that there's no kind of infections from prophage, et cetera, et cetera, et cetera, right?
So I think we all know of many studies that, you know, the material was just not of good quality. And you know, you just lose like two logs in your titer, and that's it. You have no chance of seeing an effect, right? So, you know, I think it's the GMP considerations, sort of, if it's a delicate biologic. And lastly, I think, to Joe's point, like, we've learned more about defense systems.
And I think that's where a lot of the know-how that we bring to the table, based on the work from the Weizmann Institute, is actually understanding defense systems and which phage to use, right? CRISPR, right? That's the bacterial adaptive immune system, but there are so many other defense systems. And how you choose your cocktail and how you build it, and which one you select, and if you're using individually, which phage you wanna use.
All that kind of goes into the picture. So, you know, I think there's a lot of parameters that, again, I think we're all drinking our own kool aid. But feels like, you know, us and others are getting a handle, right? Like, I think we understand how to run these studies properly.
And hopefully we'll see more of this good data. Either way.
- Jessica Sacher
Yeah, oh, I have so many, so many more questions. Anything you wish they had designed differently about the DFU trial? That you're like, Oh, if we only would've, you know, collected this, or done it slightly longer, or anything that you wish you'd done differently.
- Jonathan Solomon
I think we all wanted to see a bit more microbiology data, right? But to the point that we talked about, it's really tough to be accurate in microbiology in this indication. So, unlike CF, you measure the sputum before and after, and you can just quantify and sort of it seems to make sense, and the patients are adept in it. Here, I think the microbiology is an issue, right?
So I think that's where we felt that's very risky, because we're kind of going in blind, right? If the study fails, we're not really going to know what happened, right? Like, for example, think about one of the questions and sort of bets that the company took is: we also enrolled patients that had polymicrobial infections, right? And because all the experts said, you know,
it's the head of the snake theory, which means that, right? If the patient has staph and some others, the head of the snake is staph, and if you take out staph, you should see the effect. And it worked, right? And I think we've learned a lot, right? Because think about it, this is like the first time we test this hypothesis, right? Because we're taking out only staph.
But it could have failed, it could have failed, and then we'd be scratching our heads, sort of saying, did it not have the effect, right? Like, did we reduce the bacteria? So I think I wish, and I think that's something that we're thinking, what can we do in order to just get better microbiology readouts that we have in CF? But here it's much, much more complicated.
- Jessica Sacher
On the line of polymicrobial, I've seen another. I think technoPhage has a trial going on where they have a multi-species cocktail for diabetic foot. I think it has pseudomonas and then the Acinetobacter phages in it too. But it sounds like the head of the snake theory panned out for you, and that you took out Staph and it seemed to help a lot. Do you have a sense that there is a need to have phage that target these other pathogens as well?
- Jonathan Solomon
Potentially, potentially, we might get better effects, right? We don't know, right? I'm sure it's beneficial to try to take out some of the other bacteria again. I think some of the big advantages with phage, right? This thing is safe, so if we can take out more bacteria, hopefully that's better. And again, now we have the tools to kind of test it, right?
Here we're fortunate, cause the head of the snake theory panned out, right? By the way, it's kind of funny, cause we talked to all the KOLs, they're like, of course we always knew it was true,
- Jessica Sacher
So interesting, yeah, I've heard that. There was a phase in time where we went and interviewed a bunch of like, diabetic foot doctors in various places. And yeah, they just had such a handle over, at least, like their mental model of what these infections are. And they're just like, Yes, take out Staph.
- Jonathan Solomon
Right, but you know, you know how it is. Sometimes you kind of overthink these things and you can be really worried. Because you could say, wait a minute, wait a minute. I remember that in our CF study, you can sometimes culture more than one strain of Pseudomonas, right? So does your phage cocktail have to be sensitive to, you know, kind of all of them? And maybe we haven't captured all of them, maybe we didn't grow all of them, right? And it's sort of like you're like panicking before the clinical study and in the end just got to do the study and see what happens.
- Joe Campbell
Yeah, I think that's, you know, sometimes you do just have to, as they say, do the experiment.
- Jessica Sacher
I hate when they say that.
- Joe Campbell
As someone
- Jonathan Solomon
I feel you.
- Joe Campbell
who worked at the bench next to me back when I was doing bench science used to say, do the blanking experiment, but I mean, I guess, and you know, that's true. That was in a yeast cell biology lab where you could do the effing experiment in a day or two, and you didn't have to enroll patients and invest so much. I mean, I guess you still wanna do the blanking experiment. But I guess the question is, and Jessica alluded to it a little bit, and I know that from hearing some of the other stuff that you've done. Can you talk a little bit about the importance of talking to clinicians and seeing, you know, I guess, just sort of like, when?
When an antibiotic works, what do you reasonably see and in what timeframe? Because it seems to me more and more that if you don't have those conversations, you're gonna ask the phage to do something that even antibiotics don't do when the bug is sensitive. And that's, I think, in some cases, been a huge problem for people who are trying to get the phages to do something that someone would never expect an antibiotic to do. And so, I guess if you could talk a little bit about the need for that and how you've used discussions with people who deal with this condition all the time.
- Jonathan Solomon
So I think you're hitting the nail on the head, right? It's sort of crucial because in the end, right? We're all a bunch of scientists and we're not the physicians. I'm more like a scientist wannabe, but let's put that aside. But you know, the real people, the real scientists in the room, right? They're sort of like they're making the cocktail, they're thinking about all the stuff, but they're not treating patients, right?
And it's very different. Because, you know, again, think about, like, in our diabetic foot osteomyelitis studies, right? These patients are getting antibiotics. So we kind of talk to everyone, kind of say, it kind of goes to the question of dynamic range, like, what can we expect to see? And the experts told us, look, they are being treated on antibiotics. So in twelve weeks, you should see a reduction of 40 percent in the size of the ulcer on the placebo group, right?
- Jessica Sacher
Wow.
- Jonathan Solomon
Because, you know, it's a dire condition, by the way, it's horrendous. DFO like 40 percent of the patients end up with an amputation, right? This is no joke. And the ulcer does shrink. So then you kind of say, okay, well, if placebo is shrinking by 40 percent, what do you guys want my phage treatment to be, right? Because is it 5 percent? Is it ten percent? And they're like, no, it's got to be 20 to 30 percent, because if you don't do anything beyond that, then it's not really moving the needle, right?
So I think those are the conversations that you wanna have. And then they kind of suggested that we do, you know, sort of like the tissue involvement, meaning putting a Q tip and measuring how deep the ulcer is. That turned out to be super crucial, right? Because in our treatment, we saw an effect which was almost 40 percent, sometimes even greater than 40 percent, with stat sig that floored us, right?
Because we weren't expecting to see stat sig. And also, and this is kind of gory, but they put a Q tip and they're trying to see how deep the ulcer is. So in the 13 patients with phage that they saw that they could, literally, with a Q tip, reach the bone. Twelve of them had like significant kind of buildup of tissue over the bone after, you know, twelve weeks of treatment, and the placebo only five out of nine, right?
And some of the KOLs, by the way, to your point, kind of said, that's actually more dramatic than the ulcer size, right? Because that's really when it heals and sort of like tissue is being built on it. By the way, again, right, think about, like, I was like, wait a minute, twelve out of 13 patients. That reminds me the Wash U paper, right? Which is, it's not, which showed that, you know, twelve out of, I'm sorry, eleven out of twelve patients had recovery in DFO, right? So again, we're kind of repeating these compassionate use cases.
And they kind of deemed that the KOLs were like, this is what we want to see, this is significant, right? So you've got to be very mindful. Because to the point that we said, like, if you're not having that 30 percent improvement, right? In the end, no one would pay for an expensive phage therapy if you're not having a dramatic effect, right? So you might be jumping up and down that you had a ten percent improvement.
Maybe it's stat sig, but no one really cares, right? Because it's not clinically meaningful. And again, I think we all know, right, we all carry scars, and we know how difficult infectious diseases are, right? And I think, right, again, we're trying to kind of pursue that path, right? I think some of them make more sense than others for commercial reasons, and those are the reasons that we're trying to pursue.
I think one company that I think has been our sort of like case study, or, you know, the company we want to be, has been Insmed, right? Insmed went after a pulmonary infection called MAC, Mycobacterium avium complex. It's well over 12,000 patients in the US. They showed that after four months of treatment, the difference between placebo and treatment was like 20 percent bacterial conversion. So 20 percent of the patients kind of got rid of their infection.
That got everyone super excited. That drug is generating like 300 million in sales, right in anti-infectives, right? So, and we're like, wow, that's unbelievable. And those, by the way, in our CF study, we saw that after ten days, we had a 14 percent conversion. That's why we said, yay, we're heading in that direction if we replicate it in a large study. But there are these cases that make sense, and that's where, you know, the feedback from the KOL, the feedback from the payers, which is also crucial, right?
And the science kind of all converge to deliver something that sort of, you know, provides value for everyone.
- Jessica Sacher
Yeah, amazing. One more thing on the delivery. Did you find that the topical that you had to get, like way into the bone, or like, use a needle to get it really deep? Or was it kind of in a bandage, or how did you actually deliver it topically?
- Jonathan Solomon
No.
It was a liquid administered over a bandage. I think again some of our takeaways from playing around with topical delivery, which is much harder, right? I think in an open wound, because the environment is humid and the phage is in liquid and you close it with a bandage. It's probably the reason that the phage can propagate and diffuse and you're getting a greater effect. Like, I think our conclusion is that if you take a liquid, just put it on the skin, not in an open wound, just on semi healthy skin. It's probably not going to work, right, because it's going to dry out immediately and then the phage just won't be able to diffuse at all. So keep it in liquid, keep it very moist. And you know, most of the wound is probably accessible from that point.
- Jessica Sacher
And do you have to care about— This is kind of like back to Joe's nebulizer question. But like, did you have to screen a bunch of different types of bandages that wouldn't stick to phages too much? Or was that really a concern of yours?
- Jonathan Solomon
We did some work, but I think overall it kind of, you know, we try to be as much as we can with standard of care, right? Same with like, nebulizers, you don't want any freaky nebulizer that they'll, you know, need to get like a new house to contain, right?
- Jessica Sacher
Yeah, get a different type.
- Jonathan Solomon
So we gotta consider the patients as well, and compliance, of course.
- Jessica Sacher
Yep. And so looking forward for the next, what's next for this? How do you build on this trial? You design a bigger trial or a different one, or what's next?
- Jonathan Solomon
So one of the really interesting things with the diabetic foot osteomyelitis study is that most of it is actually funded by the Defense Health Agency and the folks at the Navy. They put a significant amount of capital into this, right? And one might ask, why, right? And they're actually closely monitoring what's happening in the Ukraine, with troops coming back with like super resistant infections. So they've been a big partner and supporter of, I mean, it's like the CF Foundation was in the CF study.
So obviously we're talking to them and kind of thinking about the next steps. But basically, it would be a larger study. I think there is a chance potentially to go for a pivotal study. This could be, you know, an orphan indication, you know, this quality of data could qualify potentially for breakthrough. So there's a lot of possibilities and flexibility to take it forward. But, you know, again, right, finally, finally, we have that phase two data.
And I think we want to just move as quickly as we can forward and just take into consideration, like the partners that are involved and have been a big supporter and funder of the program.
- Joe Campbell
I'm just assuming this is the U.S. military, right?
- Jonathan Solomon
Yes, it is, it is.
- Joe Campbell
Have you had any conversations with the Israeli military? Or is that classified? Sorry, just kidding.
- Jonathan Solomon
No, no, it's again. I don't think they have the scale that the Navy can put into place, right? Unfortunately, we know drug development is so expensive that you need a very large scale. So, you know, at least to my knowledge, the Israelis have not been doing at least biology on this scale. Definitely other stuff, right, but not biology in that case. So I think the U.S. Navy and the Defense Health Agency are kind of our go-to partner in this.
- Jessica Sacher
And when you do scale it up on the phage side, do you see the personalized one phage with a phageogram ahead of time being the approach, even in the larger scales? Or would you have to develop a cocktail based on the data to get it to the full scale that you'd want?
- Jonathan Solomon
So I think we need to make the decision. In the case of Staph aureus, we have the flexibility, right? We have a lot of experience both with cocktails as well as the personalized. So I think we'll need to make that decision pretty quickly. In general, you know, to your point, I think there are some indications that a cocktail will be the right way to go, and some of them, you know, you have to be personalized, right?
So I think Staph aureus, you have the flexibility. You know, if we're talking about Insmed… A bacterium like mycobacterium, which, you know, Graham Hatfull has done some great work on, right? That's such a difficult bacterium. I can't believe you can develop a cocktail, right? So that's got to be personalized. [Reader note — Insmed makes Arikayce, an inhaled amikacin antibiotic approved in the U.S. for certain adults with refractory Mycobacterium avium complex lung disease. Insmed reported a U.S. wholesale list price of about $16,900 per package in January 2026.]
- Jessica Sacher
I like to go off of what you were saying about the funders. And obviously the elephant in the room is that funding in the U.S. government is shaking up a lot, especially with biomedical research. And infectious disease is sort of seeming on the chopping block. How are you thinking about that, and how is that playing out for you? Is it like, as bad as it sounds like it is?
I know we're all kind of watching this.
- Jonathan Solomon
Yeah, the answer is, we don't know, right? We'll have to wait patiently and see. On the one hand, right? Like defense tech is sort of like booming to some aspect, right? The fact that everyone's sort of like, you know, building up their, you know, reservoirs and arming, et cetera, should be interesting. Because again, you know, the Navy's sort of seeing what's happening in the Ukraine, right?
It's kind of crazy, right? Troops are coming back with like, very resistant infections. You know, the war in the Ukraine looks like World War I. You know, they're in the trenches and they're infected by everything in the mud. So I think there's a clear need, so I'm sure there's a path on that aspect. Again, I think it's been challenging, right? We've all had these issues.
I think we've been fortunate to have great supporters, you know, Deerfield, the CF Foundation, the AMR Action Fund, OrbiMed, Nantahala. But again, this has not been a walk in the park, right? This is not like with the companies that usually sort of fund big oncology studies. So I think it remains a challenge. On the one hand, right? We're sort of saying, you're seeing all this talk about antibiotic resistance and, you know, sort of the next pandemic.
But we're not benefiting from the resources that we want to see, right? So I definitely think it's a challenge, but we've been fortunate with the funders that we have. But this has not been easy. And you know, it's going to be more challenging going forward because it's going to require more capital, right? As we make progress, we just need more money to do bigger studies. So again, it's good to get partners such as, you know, non-dilutive partners such as the folks at the Department of Health, the Defense Health Agency.
You know, I hope that, you know what we all wish for. Like, getting positive phase two data opens up more BD opportunities as well. Like, I think pharma will need to kind of enter the space, so let's hope we see that as well.
- Joe Campbell
So, I mean, obviously non dilutive funding is preferred, but I mean, do you talk to venture capitalists and are they feeling? I mean, one of sort of the naive thoughts is as the government pulls back, you know, I guess, how does that affect venture capitalists' view as to when they think it's a good investment to get in, to get into this space?
- Jonathan Solomon
Yeah, I don't have a good answer. You know, I'm the entrepreneur, right? So I just knock on everyone's door and nag them to death and hope that they'll invest in hope of having to spend less time with me. But I will say, some of the bankers that we talked to said that in the last few weeks, last two weeks, investors have been hiding under their desks, right?
So I think this is quite a challenging time. Let's see, right, let's see how we come out. The next few weeks, we'll see how it is. It's not easy out there, right? Like, I think biotech had a very nasty run, which makes it extremely tough. I hope that with more advanced clinical data, it's easier, right? And I think what we're trying to tell people like with phage, you don't have the risk of safety, right?
This is a safe modality. We're choosing targets which have been validated, right? We all know you want to take out Staph aureus and Pseudomonas. And hopefully the data that we've just generated in both studies is a major de-risking, right? So the risk is rather low for an unmet need. I think we're trying to talk to potential partners and saying, look, what's really interesting about phage is, say, you wanna go after Mycobacterium, right?
You can literally, you know, produce the phage cocktail right in GMP grade, hopefully within a year or so. And then you don't need to do animal studies, you don't need to do healthy volunteers, you should go straight to phase two, right? It's really attractive for a platform. It's still a difficult sell. And again, that's why I'm crossing my fingers that more of the phage companies out there will provide, you know, and deliver good data, because it's good for everyone, right?
- Jessica Sacher
Two things—you mentioned three, hm, hm, I will have to pick one first. Pharma, I feel like when I talk to people who work at pharma companies, I try to ask them, why isn't pharma investing in any antimicrobials anymore? I mean, I get why they're not. But we've had past podcast episodes diving into the pricing models. And just like the economics of making an antimicrobial actually make enough money to cover its cost is hard.
Do you think there's like, what would it take for pharma companies to actually be interested in what you guys are developing? Like, are you looking towards certain milestones that you've had conversations that, like, actually, they're not against it? It's just like certain things have to be hit that you're working toward. How do you think about all that?
- Jonathan Solomon
So I think it's two things, right? Like, I think, like, and you can understand, right? The typical pharma executive will say, Look, infectious disease is not that exciting. And phage is this new modality. I mean, it's not even a new modality, right? You guys have been talking for the last hundred years, right? Is there convincing data? Like, cause some people would say, it just doesn't work, right?
People have been talking for such a long time, it just doesn't work. Let's move on.
And I think, hopefully now, right, we put a dent in that theory. So hopefully people will be like, Hm, maybe it does work, right? Maybe it's worth taking a risk. And then the second thing is the commercial potential, and I think that's again. There are many indications that don't make sense commercially, right? Like, why? If I can treat it with the standard antibiotics, or, you know, only, like in very few cases, do I need like the fancy, expensive antibiotics?
You're not going to make any money, right? So, and again, I think that's the unfortunate reality of the field we're in. But I think people like Insmed and others have cracked it, right? Like, you know, you have MAC, right, which is a really attractive indication, right? That's generating substantial amount of sales because of the patient population. And the fact that they need it, the fact that the effect is so great, right, that it kind of makes sense, I think, to kind of give you another example: bronchiectasis, right?
So Insmed again nailed it with a study. This was an anti-inflammatory in bronchiectasis, by the way, an indication that no one touched for many, many years because everyone failed. And suddenly, you know, they kind of designed the right study and they kind of nailed it. And by the way, their market cap went from like three billion to twelve right on that positive phase three. And you think about bronchiectasis is very much like CF, right?
It's just ten times larger, right? Really interesting market that has bacterial infections, right? So there's an opportunity there. So I think it's got to be the combination of, you know, pharma companies being more comfortable with the modality, meaning we generate more good data. And B, it's got to be a really interesting indication commercially because they've been burnt, right? But there are indications in the ID space that do make sense.
- Jessica Sacher
Yeah, I've heard about this Insmed before today, just once, and I feel like I heard about it in the context of, are they able to price their antibiotic against mycobacterium differently than a typical course of antibiotics? Is it more of a like, annual chronic sort of thing, or how does that work?
- Jonathan Solomon
I know that they're charging, you know, again, the dosing can be quite long, but they're dosing like 150,000 dollars, to the best of my knowledge, right? So they can command very high prices and payers are happy to pay that, right? Because if you've converted 20 percent of the patients, right, you've completely changed the outcome of this disease, right? Like from, like, you know, someone who, just, you know, is not being able to function to like a healthy person, right?
That's really dramatic and they're willing to pay for it, right? So I think, and so large chunk of patients. So I think indication selection, and I think it goes to Joe's point about it's the KOLs, it's the pharmas and it's the payers, right. Like, you got to talk to all these different parties to understand and choose indication wisely.
- Joe Campbell
So I guess my naive thought in terms of payers paying is that the diabetic foot indications, where you know, the consequence can be amputation, which I think would be something that I would think, naively, an insurance company would go: We'll pay a lot to reduce the number of amputations among our patients. But
- Jonathan Solomon
So that's our bet. I got to give the credit to the folks at Adaptive and Deerfield, our lead investor, for doing a lot of the work in choosing that indication. But yes, think about it, the numbers are insane. There are 160,000 lower limb amputations in patients with diabetes alone. 85 percent of them are driven by DFO, right? So just think about the number of amputations. As I said, there are like 200,000 patients in the US
with DFO. Say half of them have Staph aureus. That's pretty much a number slightly less than half. And if you have DFO, the patient will end up 40 percent of the time with an amputation. By the way, the five year survival after an amputation is like 50 percent, right? That means it's worse than cancer, like it's worse than the worst cancer. So it is a big unmet need with very large numbers.
And just think about the cost, the direct cost of the amputation, just the direct cost, not the indirect cost, is 50,000 dollars, right? So I do think there's a large market and a large opportunity. Again, you know, we have to prove it, but the numbers, in our view, do add up to sort of signal something very, very significant.
- Jessica Sacher
And it still qualifies as an orphan indication, did you say earlier?
- Jonathan Solomon
Yeah, yeah, you can.
- Jessica Sacher
Yeah, yeah. And do investors actually get excited about those kind of things? Like, I feel like there's the orphan designation and also the maybe fast track kind of or breakthrough statuses that you can get.
Are you able to get all of those for what you're doing?
- Jonathan Solomon
So we got fast track and orphan in CF, and I think DFO is now next because we now have the data. So that's definitely in the cards. And you're totally right, and I think that's something really smart we heard from our investors: look, you're a biotech company, right? You got to be smart in the way you develop. And you want to choose, you know, an orphan indication for its benefits.
Just because it's so hard, just trying to do everything you can to shorten development timeline, reduce the cost of the studies, reduce the number of patients, et cetera.
- Jessica Sacher
Yep, yep, yeah, and the shifts. I also wanted to touch on the FDA. Obviously there's so many shifts happening over there. First, I wanna know like, is that impacting you now? And then, on the positive side, I saw something out that FDA had said that they're not gonna require animal studies as much. Does that factor into things? I think the phage field has already kind of benefited from being able to skip some of that already. So,
- Jonathan Solomon
Right.
- Jessica Sacher
Yeah.
- Jonathan Solomon
I think again, I got to say, our interaction with the regulatory agencies was very favorable, right? So I hope nothing changes. Because they were fantastic. I think we didn't need to do animal, at least. The FDA in three public workshops said there's no need to do animal studies and no need to do healthy volunteers. So I think we've gotten a lot of support from the agency, very open minded.
I think we're gearing up to discuss with them real-world evidence and sort of exploring microbiology endpoints for our CF study, and that's a study that will take place later this year. So again, I don't know. We don't have perspective of the changes right now, but I must say that the agency, to this date, has been super supportive. Open discussions were also very, very scientific. You know, there was a lot of consideration.
I think you spoke in some of the earlier podcasts about manufacturing and right, like whether it causes generalized transduction and harmful genes. And again, everything was to the point, practical, and, you know, just, you know, the dynamics were just very, very good. So let's just hope it stays the same. If it improves, even better, right? But let's hope it stays the same.
- Joe Campbell
So, if I could ask a very specific question regarding the FDA and something I've always been curious about for a while, is that you mentioned, I think you have around 50 Staph phages and that you're sort of screening among those phages for the phage that's going to be used in the DFO study for an individual patient. And I've always been curious about that. Because I guess it's a little bit like CAR T treatment for cancer. In the sense that I could imagine a scenario where, like, you conduct a successful clinical trial and you only use 20 of the 50 phages that you have. And then you're presented with this possibility that you could get an indication. And then for the first patient treated post-indication, a phage that's one of the 30 that wasn't involved in the study is the phage that you decide to select.
So in that sense, it would be the process of how you pick the phages and how you pick that phage for that patient, rather than the fact that that phage has been in the clinic at all. How have you had conversations, broad conversations, or specific conversations with the FDA or other regulatory agencies around that topic?
- Jonathan Solomon
Not at that level. I mean, you got to remember, I think that's sort of like, what again, right? It kind of goes to our conversation, like worrying and doing the experiment. Think about even just with standard antibiotics, like their coverage in strains is like 90 percent, 85 percent, right? So even standard antibiotics don't cover all the patients, right? And they don't test for sensitivity either; just do the clinical study.
So we, I think it's one of the things we worry about. What are the next steps in DFO, right? Obviously, you know, I'm optimistic that it'll be less of an issue than we think. That's what we've seen in CF and to some extent also in DFO, right, like in CF, we put together the cocktail again. We did make sure we tested and we made sure of the sensitivity.
But then it opened up this discussion, like, wait a minute, are we culturing all the strains there? Maybe there's other strains, maybe different parts of the lung might have like different strains, right? And do we really know the full picture? And we don't know, right? And then you just try, you kind of say, okay, let's just do the experiment. So I suspect, you know how it is.
We'll have to choose the bank of phage that we'll produce, whether it's a cocktail or sort of the phage that we'll take forward. And we'll have to see how the clinical study looks. But again, in Staph aureus, I think it's less of an issue just based on the data we've generated to date. If this was mycobacterium, then I think we'd be really worried, right? That's a really tough one.
- Jessica Sacher
I think we should probably wrap up because we're at the top of the hour, but I have a couple rapid fire questions left.
- Jonathan Solomon
Go for it.
- Jessica Sacher
So, okay, one is I forgot to ask about quantity. How much phage do you need to get to the site, or that you need to dose, or how much did you use in this study?
- Jonathan Solomon
Yeah, we haven't disclosed it. I can say that the vials were not humongous, right? So, and the titers were not like extreme, we didn't sort of optimize super high titers. So again, it seems that there's enough phage to start, probably the amplification process, and it just worked, right? Again, that's what we used in compassionate use cases.
- Jessica Sacher
And then what if you had to say? Since our audience is very much going to be phage researchers, what research is left to do that would be the most impactful for you? Like, if you saw a paper published tomorrow, finally answering some question about Staph phage biology, or even maybe on the pharmacokinetic side, what are you thinking?
- Jonathan Solomon
So I think there's a lot of great work happening right now in defense systems, so that field is sort of like moving. The field that has sort of surprised me that there isn't that much work is actually biofilm, right? I think there's a lot to learn about biofilm in DFO, you can literally image the biofilm, and, you know, we use our assays for biofilm. But I suspect that there's so much more work that we can do in biofilm to harmonize assays and understand.
By the way, sometimes biofilm could be polymicrobial, right? So what does that mean? And we know that the bacteria produce different biofilms in different conditions. And so I think that's one field that we're surprised that there isn't a lot more work. Because I suspect that that's one of the leading causes for failure of standard therapy, right, of antibiotic therapy.
- Jessica Sacher
Right? Okay, so researchers, please study the biofilm formation.
- Jonathan Solomon
And let us know, reach out to us, cause we're sweating.
- Jessica Sacher
Okay, yeah, maybe. Would you collaborate with academics if they had a new assay for biofilm or something like that?
- Jonathan Solomon
All the time, all the time, as much as we can.
- Jessica Sacher
Awesome. The final kind of question that we ask everyone is about where you hope and expect BiomX to be in the future. So the five year and the 15 year.
- Jonathan Solomon
So we had this discussion already internally in the company five years ago and wanted to be now with like two programs in phase two. And somehow we got there. So I think we're very fortunate again, thanks to the hard work of the BiomX team and the Adaptive phage team. In five years from now, hopefully we have like one or two approved drugs. In 15 years, we want to be sort of a go to modality, right?
We want to have multiple programs that we address. I mean, I'm sure some of the cases of infections will be treated with small molecule antibiotics because it's better. But I hope that there'll be more and more indications that we can pursue. And also, I think, going back to where we started, more chronic disease, such as inflammatory bowel disease and some of the others, which are really much tougher. Once we feel comfortable with a modality, we can start exploring the target.
- Jessica Sacher
Some of the ones that BiomX started before you guys merged with APT.
- Jonathan Solomon
Right, before we put it on ice and focused on infectious disease. I think we'd love to kind of revisit that, but later.
- Jessica Sacher
Yep, awesome. Anything else, Joe?
- Joe Campbell
No, as usual, I could ask questions forever, but I think in the interest of time, this has been great. We hit a lot of important issues and thank you for your thoughtful responses and taking the time to talk to us. We always appreciate that.
- Jonathan Solomon
No. It's a pleasure and keep up the great work. You know, hopefully we want more people in the field, so we're at your service to help in anything and keep up the great stuff you're doing. The field needs it.
- Jessica Sacher
Thank you, thank you so much for being here. This was so much fun. See you around.
- Joe Campbell
Okay.
